ADC Therapeutics SA Long Term Debt 2019-2022 | ADCT

ADC Therapeutics SA long term debt from 2019 to 2022. Long term debt can be defined as the sum of all long term debt fields.
ADC Therapeutics SA Annual Long Term Debt
(Millions of US $)
2021 $125
2020 $108
2019 $
2018 $
ADC Therapeutics SA Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $97
2022-03-31 $111
2021-12-31 $125
2021-09-30 $142
2021-06-30 $134
2021-03-31 $88
2020-12-31 $108
2020-09-30 $107
2020-06-30 $140
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.141B 9.65
GSK (GSK) United Kingdom $71.077B 8.53
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.276B 18.88
Biohaven Pharmaceutical Holding (BHVN) United States $10.581B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.200B 0.00
Arcus Biosciences (RCUS) United States $2.020B 39.44
Myovant Sciences (MYOV) United Kingdom $1.765B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.418B 0.00
Enzo Biochem (ENZ) United States $0.133B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00